Logicbio therapeutics, inc. (LOGC)
CashFlow / Yearly
Dec'19Dec'18Dec'17
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-40,128

-17,621

-5,795

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense

289

89

-

Depreciation expense

-

-

43

Loss on disposal of property and equipment

-

-140

-

Net amortization of premiums and discounts on investments

436

-

-

Stock-based compensation expense

1,807

1,104

460

Non-cash interest expense

101

-

-

Non-cash lease expense

1,168

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

777

150

1,032

Other assets

-

-249

-

Other non-current assets

-

-

-249

Accounts payable

-527

35

771

Accrued expenses and other current liabilities

-247

887

20

Net cash used in operating activities

-38,750

-15,267

-5,782

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of investments

58,490

-

-

Maturities of investments

41,400

-

-

Purchase of property and equipment

1,415

614

36

Disposal of property and equipment

-

35

-

Net cash provided by (used in) investing activities

-18,505

-579

-36

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock from the initial public offering

-

74,865

-

Proceeds from borrowings under loan and security agreement, net of issuance costs

9,845

-

-

Proceeds from exercise of stock options

224

20

-

Payment of deferred initial public offering costs

-

2,579

-

Net cash provided by financing activities

10,069

72,306

28,703

Effect on foreign exchange rates on cash and cash equivalents

9

17

-38

NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

-47,177

56,477

22,847

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest

445

-

14

Cash paid for income taxes

6

164

4

Right-of-use assets obtained in exchange for operating lease obligation

1,461

-

-

Property and equipment purchases in accounts payable and accrued expenses

-

20

-

SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES:
Deferred initial offering costs in accounts payable and accrued expenses

-

32

-

Conversion of preferred stock to common stock from the initial public offering

-

33,062

-

Warrants issued in connection with loan and security agreement

136

-

-

Series B Convertible Preferred Stock [Member]
Proceeds from issuance of preferred stock

-

-

29,181

Payment of issuance costs

-

-

478